Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.

PHASE2CompletedINTERVENTIONAL
Enrollment

175

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

August 31, 2003

Study Completion Date

June 30, 2004

Conditions
Mild Cognitive Impairment
Interventions
DRUG

CX516

DRUG

Placebo

Trial Locations (8)

15213

University of Pittsburgh, Pittsburgh

33617

Sun Coast Gerontology Center, University of South Florida, Tampa

50314

Mercy Mayo Clinic, Des Moines

85381

Pivotal Research Centers, Peoria

90095

University of California at Los Angeles, Los Angeles

92093

University of California, San Diego, San Diego

92697

University of California Irvine, Irvine

06510

Yale University School of Medicine, New Haven

All Listed Sponsors
lead

RespireRx

INDUSTRY

NCT00040443 - Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment. | Biotech Hunter | Biotech Hunter